The simple use of HTA can not be an excuse for delays. Many countries using HTA deliver faster-funded access to medicine and other health technologies. Australia's issue is that its statutory framework for applying HTA to the PBS, which has been extended or used as the policy basis for other programs, was designed and intended to cause delays.
Delays were the intended outcome, not an unintended consequence
January 13, 2025 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 12, 2025 - - Latest News -
Rare Cancers Australia says election is the chance to end the ‘cancer lottery’
February 12, 2025 - - Latest News -
Specialised Therapeutics announces Thai approval of breast cancer therapy
February 12, 2025 - - Latest News -
Merck adds experienced industry executive to leadership team
February 11, 2025 - - Latest News -
Sandoz summit promotes reform to boost the use of biosimilars
February 11, 2025 - - Latest News -
AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies
February 11, 2025 - - Latest News -
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 - - Latest News